Cancer neoantigen: Boosting immunotherapy

Peijia Xu; Haiqing Luo; Ying Kong; Wing-Fu Lai; Liao Cui; Xiao Zhu

doi:10.1016/j.biopha.2020.110640

Cancer neoantigen: Boosting immunotherapy

Biomed Pharmacother. 2020 Nov:131:110640. doi: 10.1016/j.biopha.2020.110640. Epub 2020 Aug 21.

Authors

Peijia Xu¹, Haiqing Luo², Ying Kong³, Wing-Fu Lai⁴, Liao Cui⁵, Xiao Zhu⁶

Affiliations

¹ Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, 524023, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, 524023, China.
² Cancer Center, Affiliated Hospital, Guangdong Medical University, Zhanjiang, 524023, China.
³ Department of Clinical Laboratory, Hubei No. 3 People's Hospital of Jianghan University, Wuhan, 430033, China.
⁴ Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China; School of Life and Health Sciences, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China. Electronic address: rori0610@graduate.hku.hk.
⁵ Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, 524023, China. Electronic address: cuiliao@163.com.
⁶ Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, 524023, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, 524023, China; Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, 524023, China. Electronic address: xzhu@gdmu.edu.cn.

PMID: 32836075
DOI: 10.1016/j.biopha.2020.110640

Abstract

Tumor neoantigen has a high degree of immunogenicity. As one of the emerging methods of tumor immunotherapy, the vaccine developed against it has served to clinical trials of various solid tumors, especially in the treatment of melanoma. Currently, a variety of immunotherapy methods have been applied to the treatment of the tumor. However, other therapeutic methods have the disadvantages of low specificity and prominent side effects. Treatments require tumor antigen with higher immunogenicity as the target of immune attack. This review will recommend the identification of neoantigen, the influencing factors of neoantigen, and the application of personalized vaccines for neoantigen in metastatic tumors such as malignant melanoma.

Keywords: Immunotherapy; Melanoma; Neoantigen; Personalized vaccine; Tumor mutational burden.

Publication types

Review

MeSH terms

Animals
Antigens, Neoplasm* / genetics
Antigens, Neoplasm* / immunology
Cancer Vaccines / administration & dosage*
Cancer Vaccines / genetics
Cancer Vaccines / immunology
Humans
Immunotherapy / methods*
Immunotherapy / trends
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / therapy*
Precision Medicine / methods*
Precision Medicine / trends

Substances

Antigens, Neoplasm
Cancer Vaccines